Herbal pill may boost exercise in heart stent patients

NCT ID NCT03809273

Disease control Sponsor: Shenyang Northern Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether Yangxinshi pills, a traditional Chinese medicine, can improve exercise tolerance in people who recently had a heart stent (PCI). Over 600 participants received either Yangxinshi or the drug Trimetazidine for comparison. The main goal was to see if Yangxinshi helps patients do more physical activity without chest pain or other heart issues.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Yangxinshi pill (herbal) and Trimetazidine (drug)
What this could lead to: If Yangxinshi works as well as or better than Trimetazidine, it could offer a new option to help heart patients exercise more easily after stent placement.
What could go wrong: This is a completed phase 4 trial, but results are not yet published. The herbal nature of Yangxinshi means its exact active ingredients and long-term effects are less understood than standard drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

681 people

The number who actually took part.

Started

Aug 2019

Finished

Dec 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18\~ 75, gender is not limited； * The patient within two month after PCI operation for the first time； * The patient had 1-2 coronary artery lesions with complete revascularization：At least one drug eluting stent was implanted，and residual coronary artery stenosis after PCI \<30%； * Have not revascularization plan within 6 months； * After being evaluated by clinicians on aerobic exercise ability，patients can carry out early rehabilitation in hospital and exercise cardiopulmonary rehabilitation outside the hospital； * Coronary heart disease patients with Qi Deficiency and Blood Stasis Syndrome； * Participants voluntarily participated in and signed informed consent； Exclusion Criteria: * Patients was diagnosed with AMI as the first diagnosis in the past month, and then hospitalized for PCI operation； * Patients with absolute and relative contraindications in cardiopulmonary exercise test； * Any drug allergy to Yangxinshi pill and trimetazidine； * Patients have taken regular Yangxinshi pill, trimetazidine or other Chinese patent medicine regularly in the past month； * Patients are intolerant of aspirin, clopidogrel, statins, beta blockers or ACEI drugs (such as massive hemorrhage, severe hypotension, etc.)； * History of stroke (cerebral hemorrhage, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism and stroke of unknown type) or lower extremity arterial disease in the past 6 months * Active bleeding disease within 6 months； * Combined with severe liver and kidney dysfunction (creatinine clearance ≤ 30ml / min or in the active stage of kidney disease, serum aminotransferase ≥ 3 × upper limit of clinical reference), other lifethreatening serious primary or psychiatric diseases and malignant tumors * Hemoglobin \<90 g/L； * Cardiac function (NYHA) grade IV or echocardiography LVEF \< 30%； * Venous blood pressure \<100/60 mmHg； * In past 6 months, have medical history of: pregnancy, prepare or suspected of pregnancy, abortion, breastfeeding or after childbirth * The expected survival period is less than one year.； * Patients who are participating in other clinical studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Percutaneous coronary intervention

Contacts and locations

Locations

Beijing Anzhen Hospital, Capital Medical University

Beijing, Beijing Municipality, China
Cangzhou Central Hospital

Cangzhou, Hebei, China
Changchun Traditional Medicine University Affiliated Hospital

Changchun, Jilin, China
First Hospital of Shanxi Medical University

Taiyuan, Shanxi, China
General Hospital of Northern Theater Command

Shenyang, Liaoning, 110016, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China
Hebei General Hospital

Shijiazhuang, Hebei, China
Jinan Central Hospital Affiliated to Shandong University

Jinan, Shandong, China
Peking University People's Hospital

Beijing, Beijing Municipality, China
Qingdao Municipal Hospital

Qingdao, Shandong, China
Shandong Provincial Hospital

Jinan, Shandong, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, China
The Second Hospital of Dalian Medical University

Dalian, Liaoning, China
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.